Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.

Frederick J RaalDavid KallendKausik K RayTraci TurnerWolfgang KoenigR Scott WrightPeter L J WijngaardDanielle CurcioMark J JarosLawrence A LeiterJohn J P Kasteleinnull null

Published in: The New England journal of medicine (2020)

Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had significantly lower levels of LDL cholesterol than those who received placebo, with an infrequent dosing regimen and an acceptable safety profile. (Funded by the Medicines Company; ORION-9 ClinicalTrials.gov number, NCT03397121.).

Keyphrases

early onset
low density lipoprotein
randomized controlled trial
double blind
phase iii